 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 02/11/2005 | | | | Nymox's Alzheimer Urine Test Now Available as Kit in Europe
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
February 11, 2005: Nymox Pharmaceutical Corporation announced today that there will be distribution agreements for the marketing and sale of
its AlzheimAlert™ test kit with medical diagnostic companies in Europe. Nymox has announced the certification of its AlzheimAlert™ test kit with a CE Mark, making the device available for sale in the European Union. |
| 02/02/2005 | | | | Childhood Exposure to Second Hand Smoke Increases Lung Cancer Risk for Adults According to New Study
topic: Tobacco Exposure Tests
February 2, 2005: A new study published in the online edition of the British
Medical Journal has found evidence that childhood exposure to second hand smoke
increases the risk of acquiring lung cancer as an adult. The researchers conducted a seven year follow-up of
60,182 non-smokers as part of a large ongoing European study. They found that adults
reporting exposure to second hand smoke in childhood were more at risk for lung cancer as
compared to unexposed adults. Adults who reported daily childhood second hand smoke had
twice the risk of lung cancer; those reporting heavy daily exposure had over three and a
half times the risk. |
| 01/18/2005 | | | | Second Hand Smoke Adversely Affects Children's Reading Scores, Math Skills and Reasoning Abilities
topic: Tobacco Exposure Tests
January 18, 2005: Exposure to second hand smoke adversely affects
children's reading scores, math skills and reasoning abilities according to a new study published in this month's Environmental Health Perspectives (Jan 2005; 113(1):
98-103). |
| 12/02/2004 | | | | Nymox Files Data with FDA for Alzheimer Urine Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
December 2, 2004: Nymox Pharmaceutical Corporation announced today that it has filed an amendment to its Premarket Approval application (PMA)for the Company's urine NTP test kit with the FDA. The new PMA amendment is filed in response to the remaining requirements from the Company's meetings and discussions with the FDA. |
| 11/23/2004 | | | | Nymox Pharmaceutical Rated “Bullish” by Standard & Poor's Stock Reports
topic: Financial
November 23, 2004: Nymox Pharmaceutical Corporation receives favorable coverage in a new Standard & Poor's Stock Report. |
| 11/22/2004 | | | | Alzheimer's Disease Identified as a Priority for Europe in World Health Organization Study
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
November 22, 2004: A landmark new report by the World Health Organization for the European Union has identified Alzheimer's disease as a major healthcare priority for Europe. A major concern emphasized by the report was for technology for the diagnosis of Alzheimer's disease. Nymox recently announced the certification of its AlzheimAlert™ test kit with a CE Mark, making the device eligible for sale in the European Union. |
| 11/15/2004 | | | | Nymox Reports Third Quarter 2004 Financial Results
topic: Financial
November 15, 2004: Nymox Pharmaceutical Corporation announced today its financial results for the third quarter of 2004. |
| 11/10/2004 | | | | Taking Statin Slowed Progression of Alzheimer's Disease According to New Study
topic: Statins and Alzheimer's Disease
November 10, 2004: A new study has found evidence that taking a
commonly prescribed cholesterol-lowering statin drug slowed cognitive decline and improved
depressive symptoms in patients with mild to moderate Alzheimer's disease. |
| 11/08/2004 | | | | Nymox Obtains CE Mark for AlzheimAlert™ Test Kit; Product Now Available in Europe
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
November 8, 2004: Nymox Pharmaceutical Corporation is
pleased to announce the certification of its AlzheimAlert™ test kit with a CE Mark,
making the device eligible for sale in the European Union. The Company announced today
that it has now fulfilled the required regulations which will allow European clinical and
hospital laboratories to perform the AlzheimAlert™ test in their own facilities in
Europe. |
| 11/04/2004 | | | | Nymox Files PMA Amendment with FDA for Alzheimer Urine Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
November 4, 2004: Nymox Pharmaceutical Corporation announced today that it has filed an amendment to its Premarket Approval application (PMA)
for the Company's urine NTP test kit with the FDA. The PMA amendment was filed in response
to the Company's discussions and meetings with the FDA. The Company believes that the
remaining requirements from the Company's meetings and discussions with the FDA will be
completed and filed in the next 30 to 60 days. |
|